Australia medical device regulations

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

An ARTG variation must preserve the same kind of device: sponsor, manufacturer, GMDN, class and the applicable prescribed characteristics/UPI. For manufacturer name or address changes, TGA checks whether responsibility for design, production, packaging and labelling and the QMS remain the same. A same-entity office/name update with unchanged QMS can be accepted; changed control or QMS can require a new inclusion. A sponsor transfer is a different legal event.

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

Under Regulations 10F/10FA, qualifying sponsor succession/assignment and sponsor-name events are notified in the approved manner within three months. An agreed business/interest transfer carries the inclusion to the new sponsor when the event occurs; it is not a discretionary transfer by a foreign manufacturer. A same sponsor with unchanged ABN/ACN uses the name form; changed ABN/ACN requires new organisation identification and the applicable transfer process.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

The transfer form identifies both sponsors/client IDs, affected ARTG entries, event/date and declarations by authorised representatives; extra entries use an attached list. Submit after the transfer has occurred and identify pending variations. Manufacturer Evidence is not transferred with sponsorship: the new sponsor first obtains accepted evidence, then submits DCR to link it to the ARTG. That order is separate from the legal event transferring sponsorship.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

There is no fee for the sponsor transfer/name notification itself. TGA says it normally updates the ARTG within ten working days of a fully completed, signed notification and any required information; the form describes this as an aim. This administrative processing target does not defer legal sponsorship responsibility until the record is updated or price additional ARTG variations.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

For MDs, the Class III/AIMD variation form addresses UPI, total-device count, functional description or variants; other relevant updates generally use DCR. Support the actual change with sponsor explanation, manufacturer/notified-body evidence and applicable DoC, design certificate, IFU, label, surgical technique and significant-change approval. Where the certification change requires notified-body approval, complete that before seeking the ARTG variation. Wait for the ARTG decision before implementation.

Under Regulations 10F/10FA, qualifying sponsor succession/assignment and sponsor-name events are notified in the approved manner within three months. An agreed business/interest transfer carries the inclusion to the new sponsor when the event occurs; it is not a discretionary transfer by a foreign manufacturer. A same sponsor with unchanged ABN/ACN uses the name form; changed ABN/ACN requires new organisation identification and the applicable transfer process.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

The transfer form identifies both sponsors/client IDs, affected ARTG entries, event/date and declarations by authorised representatives; extra entries use an attached list. Submit after the transfer has occurred and identify pending variations. Manufacturer Evidence is not transferred with sponsorship: the new sponsor first obtains accepted evidence, then submits DCR to link it to the ARTG. That order is separate from the legal event transferring sponsorship.

Current Schedule 9 item 2A (f) sets AUD 1133 for a non-IVD medical-device ARTG variation not covered by (g), excluding data evaluation. Item 2A (g) instead sets AUD 215 per ten entries or part only when the kind is EU-transition affected, the variation solely updates manufacturer evidence, and the same evidence is involved for all entries. General brand, name, address or REF changes do not establish those three conditions.

There is no fee for the sponsor transfer/name notification itself. TGA says it normally updates the ARTG within ten working days of a fully completed, signed notification and any required information; the form describes this as an aim. This administrative processing target does not defer legal sponsorship responsibility until the record is updated or price additional ARTG variations.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

Device information may be supplied in multiple languages, but if the device is supplied in Australia one of those languages must be English; information supplied with the device must be clear, legible and provided in English. Labelling content requirements are in Essential Principle 13 (Schedule 1, MD Regulations) and the sponsor's name and address must appear on supplied devices under Regulation 10.2.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.